Tonix Pharmaceuticals Q3 EPS $(2.89) Misses $(2.31) Estimate, Sales $17.200M Beat $16.717M Estimate
Benzinga Newsdesk 6 hours ago
NewsEarningsEarnings BeatsEarnings Misses
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.89) per share which missed the analyst consensus estimate of $(2.31) by 25.11 percent. This is a 19.5 percent increase over losses of $(3.59) per
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.89) per share which missed the analyst consensus estimate of $(2.31) by 25.11 percent. This is a 19.5 percent increase over losses of $(3.59) per share from the same period last year. The company reported quarterly sales of $17.200 million which beat the analyst consensus estimate of $16.717 million by 2.89 percent. This is a 422.80 percent increase over sales of $3.290 million the same period last year.